tetano
Editor, Senior Moderator
Vaccine
. 2021 Sep 3;S0264-410X(21)01165-8.
doi: 10.1016/j.vaccine.2021.08.103. Online ahead of print.
Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19
Zehua Zhou[SUP] 1 [/SUP], Xinyu Zhang[SUP] 2 [/SUP], Qianqian Li[SUP] 3 [/SUP], Lili Fu[SUP] 3 [/SUP], Meiyu Wang[SUP] 3 [/SUP], Shuo Liu[SUP] 3 [/SUP], Jiajing Wu[SUP] 3 [/SUP], Jianhui Nie[SUP] 3 [/SUP], Li Zhang[SUP] 3 [/SUP], Chenyan Zhao[SUP] 3 [/SUP], Fei Jiang[SUP] 3 [/SUP], Yimeng An[SUP] 3 [/SUP], Bin Yu[SUP] 4 [/SUP], Haifa Zheng[SUP] 5 [/SUP], Youchun Wang[SUP] 6 [/SUP], Aihua Zhao[SUP] 7 [/SUP], Weijin Huang[SUP] 8 [/SUP]
Affiliations
Abstract
The development of an effective vaccine to control the global coronavirus disease-2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus- 2 (SARS-CoV-2) is of utmost importance. In this study, a synthetic DNA-based vaccine candidate, known as pSV10-SARS-CoV-2, expressing the SARS-CoV-2 spike protein was designed and tested in 39 BALB/c mice with BC01, an adjuvant derived from unmethylated CpG motif-containing DNA fragments from the Bacillus Calmette-Guerin genome. Mice vaccinated with pSV10-SARS-CoV-2 with BC01 produced early neutralizing antibodies and developed stronger humoral and cellular immune responses compared to mice that received the DNA vaccine only. Moreover, sera from mice vaccinated with pSV10-SARS-CoV-2 with BC01 can neutralize certain variants, including 614G, 614G + 472 V, 452R, 483A, 501Y.V2, and B.1.1.7. The results of this study demonstrate that the addition of BC01 to a DNA-vaccine for COVID-19 could elicit more effective neutralizing antibody titers for disease prevention.
Keywords: BC01 adjuvant; COVID-19; DNA vaccine; SARS-COV-2.
. 2021 Sep 3;S0264-410X(21)01165-8.
doi: 10.1016/j.vaccine.2021.08.103. Online ahead of print.
Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19
Zehua Zhou[SUP] 1 [/SUP], Xinyu Zhang[SUP] 2 [/SUP], Qianqian Li[SUP] 3 [/SUP], Lili Fu[SUP] 3 [/SUP], Meiyu Wang[SUP] 3 [/SUP], Shuo Liu[SUP] 3 [/SUP], Jiajing Wu[SUP] 3 [/SUP], Jianhui Nie[SUP] 3 [/SUP], Li Zhang[SUP] 3 [/SUP], Chenyan Zhao[SUP] 3 [/SUP], Fei Jiang[SUP] 3 [/SUP], Yimeng An[SUP] 3 [/SUP], Bin Yu[SUP] 4 [/SUP], Haifa Zheng[SUP] 5 [/SUP], Youchun Wang[SUP] 6 [/SUP], Aihua Zhao[SUP] 7 [/SUP], Weijin Huang[SUP] 8 [/SUP]
Affiliations
- PMID: 34521552
- DOI: 10.1016/j.vaccine.2021.08.103
Abstract
The development of an effective vaccine to control the global coronavirus disease-2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus- 2 (SARS-CoV-2) is of utmost importance. In this study, a synthetic DNA-based vaccine candidate, known as pSV10-SARS-CoV-2, expressing the SARS-CoV-2 spike protein was designed and tested in 39 BALB/c mice with BC01, an adjuvant derived from unmethylated CpG motif-containing DNA fragments from the Bacillus Calmette-Guerin genome. Mice vaccinated with pSV10-SARS-CoV-2 with BC01 produced early neutralizing antibodies and developed stronger humoral and cellular immune responses compared to mice that received the DNA vaccine only. Moreover, sera from mice vaccinated with pSV10-SARS-CoV-2 with BC01 can neutralize certain variants, including 614G, 614G + 472 V, 452R, 483A, 501Y.V2, and B.1.1.7. The results of this study demonstrate that the addition of BC01 to a DNA-vaccine for COVID-19 could elicit more effective neutralizing antibody titers for disease prevention.
Keywords: BC01 adjuvant; COVID-19; DNA vaccine; SARS-COV-2.